pSivida Corp. (PSDV) President and CEO Discusses ILUVIEN News, Market Insight, and Other Company Information on New Blog
On May 23, 2013, pSivida Corp. published a new blog post on The Chairman’s Blog entitled “Big and Small Picture,” penned by company President and CEO Dr. Paul Ashton. Located at, The Chairman’s Blog is an exclusive online media publication offering key executives a platform for sharing insights about their companies and industry trends.
In the newly published blog, Dr. Ashton elaborates on the age-related macular degeneration (AMD) and chronic diabetic macular edema (DME) markets, as well as competitors in the space. He also provides an overview of recent news relating to the company’s ILUVIEN, which is a sustained-release insert that has been approved in Europe for chronic DME. Ashton further explains the company’s profit split with ILUVIEN’s licensee, Alimera Sciences.
In addition to enabling upper-tier management to discuss issues of importance to their stakeholders, shareholders, and other interested parties, features articles on such topics as finance, technology, health and energy, which have been contributed by staff and aggregate partners. The site additionally provides updated market trends, news and information.
Headquartered in Watertown, Mass., pSivida Corp. specializes in the development of tiny, sustained-release drug delivery products that are designed to release drugs at a controlled and steady rate over the course of months or years. The company is presently focused on treating chronic diseases of the back of the eye, utilizing Durasert and BioSilicon, its core technology systems. The company also has two FDA-approved products, Vitrasert and Retisert, which are licensed to Bausch & Lomb. pSivida has licensed ILUVIEN for DME to Alimera Sciences, and that product has been granted marketing authorization in Austria, France, Germany, Portugal, Spain, and the United Kingdom.
The company additionally has clinical trials ongoing for the treatment of posterior uveitis and glaucoma and ocular hypertension. Other technologies the company has in development include protein and antibody delivery systems, which are in early clinical stages. For more information, visit
To read Dr. Paul Ashton’s full blog post, visit
Please see disclaimer on the MissionIR website
Rate this post
0 stars